iconoclast,

Great points especially on a potential valuation of an RVX buyout price of $2 Billion USD based on the BT designation.  My only disagreement is on your purchase price of Zenith Epigenetics of 10 to 15% of RVX price . Talk about being in love with a company, pfizer paid $14 Billion from Mediavation for Xtandi drug for their  metastic Prostate  drug while Zenith Epigenetics is working on the same type of condition with Zenith 3694 , In my opinion Zenith could be worth more than RVX at some point, that being said there is a lot of potential for both companies to be bought out